ClinicalTrials.gg
RecruitingNCT07634861AI-REPORTUpdated Jun 9, 2026

Evaluating a Text-Prompt AI Assistant for Chest CT Scans (AI-REPORT Study)

An interventional study of AI-generated report for chest CT and Standard reporting procedure (no AI assistance) in Thoracic Diseases, sponsored by Shanghai Zhongshan Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to find out if an artificial intelligence (AI) system can help experienced radiologists write chest CT scan reports more quickly without lowering the quality of the report. Chest CT scans are common, and writing reports for them is a major part of a radiologist's job. In this trial, board-certified radiologists will interpret complex chest CT cases. For some cases, they will start with a complete draft report generated by the AI system, which they can review and edit as needed. For other cases, they will write the report from scratch without any AI help, following their usual routine. The main things we are measuring are: 1) how much time the AI draft saves, and 2) whether the final reports created with AI help are as good as or better than those written without it, as judged by other senior doctors who do not know which report came from which method. The hope is that this AI tool can make radiologists' work more efficient while maintaining high standards for patient care.

Read the detailed description

This study investigates whether an artificial intelligence (AI) system that drafts preliminary radiology reports can help experienced chest CT radiologists work faster while maintaining or improving report quality. The trial is conducted in two sequential phases. The first phase uses a set of complex, real-world historical cases. Radiologists interpret these cases both with and without the help of the AI-generated draft (AI-report) in a controlled, crossover study design. The second phase is a prospective, real-world deployment where the same AI-report system is integrated into the clinical workflow of participating radiologists as they interpret new, incoming chest CT scans in real time. We measure the time it takes to complete reports and, through blinded evaluations by other senior doctors, assess the quality of the final reports created with and without AI assistance. The goal is to determine if this AI tool can make radiologists' work more efficient and support high-quality patient care in actual practice.

1. Detailed Description

1.1 Study Design

This is a two-phase, multicenter, multireader, multicase (MRMC) study designed to evaluate the real-world clinical utility of an AI report generation system (AI-report).

  1. Stage 1 (controlled crossover evaluation): This stage employs a retrospective, randomized, two-period crossover design. A curated set of complex historical chest CT cases, previously discussed in multidisciplinary team (MDT) meetings, is used. Each participating radiologist acts as their own control, interpreting the same cases both with and without the AI draft under controlled conditions.
  2. Stage 2 (prospective real-world deployment): This stage is a prospective, observational study. The validated AI-report system is deployed into the live clinical workflow of the participating radiologists. They use the system in real-time as they interpret new, consecutive chest CT scans from their clinical duties, allowing for evaluation in an authentic clinical environment.

1.2 Objectives

  1. Primary objectives: To evaluate the impact of the AI-report system on 1) radiologist efficiency (interpretation time) and 2) the clinical quality of finalized reports, assessed in both a controlled retrospective setting (Phase 1) and a prospective real-world setting (Phase 2).
  2. Secondary objectives: To assess the nature and clinical significance of edits made to AI drafts, and to evaluate system usability and integration into the routine reporting workflow.

1.3 Study Population

  1. Radiologist Readers: Board-certified radiologists with ≥ 3 years of independent thoracic imaging practice.
  2. Blinded Evaluators: Eleven senior clinicians from the original MDT panels that contributed the Phase 1 cases, responsible for blinded quality assessment.

1.4 Intervention

The intervention is the provision of a fully AI-generated draft radiology report (AI-report). In Phase 1, this is provided within a controlled reading platform for historical cases. In Phase 2, the system is integrated into the clinical Picture Archiving and Communication System (PACS)/Radiology Information System (RIS) to generate drafts for prospective, real-time cases.

2. Study Procedures

Phase 1 (Retrospective Crossover): The 400 historical MDT cases are used. The study involves two reading rounds with a washout period. In each round, radiologists interpret a set of cases, with the AI condition (draft provided or not) randomized and crossed over between rounds. Interpretation time is recorded, and all finalized reports are collected for blinded pairwise comparison by the evaluator panel.

Phase 2 (Prospective Deployment): Following Phase 1, the AI-report system is activated in the clinical environment for participating radiologists. During a defined prospective observation period, the system generates drafts for eligible new chest CT scans. Radiologists use these drafts in their daily work. Reporting time and the AI drafts alongside the finalized human-edited reports are collected for analysis. Report quality in this phase is assessed longitudinally and through sampling.

3. Outcome Measures

3.1 Primary Outcomes:

Efficiency: Change in median interpretation time per case with vs. without AI-report assistance (Phase 1) and the distribution of reporting times during real-world use (Phase 2).

Quality: Superiority score from blinded paired comparisons of AI-assisted vs. unassisted reports (Phase 1). Qualitative and quantitative assessment of report adequacy in the prospective cohort (Phase 2).

3.2 Secondary Outcomes:

Clinical significance of radiologist modifications to AI drafts (5-point scale).

System usability and workflow integration scores from post-study surveys.

4. Statistical Analysis

Analysis will account for the MRMC design in Phase 1 using hierarchical models. Phase 2 data will be analyzed using descriptive statistics and statistical process control methods where appropriate. The two phases will be analyzed separately to provide insights into efficacy (Phase 1) and effectiveness (Phase 2).

02

Conditions studied

  • Thoracic Diseases

Browse trials for

03

In context

Thoracic Diseases

72 studies on the registry are indexed under Thoracic Diseases; 13 are open to participants now.

This study's planned enrollment of 100 is above the median of 65 across 52 interventional studies indexed under Thoracic Diseases.

Browse Thoracic Diseases studies →

Lead sponsor

Shanghai Zhongshan Hospital is the lead sponsor of 652 studies on the registry; 291 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active board certification and ongoing routine clinical practice as an attending radiologist
  • Independent institutional authority for chest CT image interpretation and final official diagnostic report issuance
  • A minimum of three years of post-certification clinical experience in specialized thoracic imaging
  • Legal and cognitive competence for study participation, with voluntary provision of written after full understanding of study purpose, procedures, risks and benefits

Exclusion criteria

Exclusion Criteria:

  • Direct participation in the development, training or validation of the trial's evaluated AI system
  • Ongoing participation in concurrent studies with potential risks of interpretation bias, cognitive fatigue or study procedure interference (investigator-assessed)
  • Any actual or perceived conflict of interest related to the evaluated AI system or its developers that may compromise objectivity in image interpretation and diagnostic reporting
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    AI-Assisted Reporting Arm

    This arm involves board-certified radiologists interpreting chest CT cases using the AI system, which generates a preliminary report draft. In Phase 1 (retrospective crossover), each radiologist interprets the same set of historical cases twice: once with the AI-generated draft and once without, with order randomized and a washout period. In Phase 2 (prospective real-world deployment), radiologists use AI drafts for consecutive new chest CT scans in routine practice. The intervention is the provision of the AI-generated report draft; no other changes to standard workflow are introduced.

    Device: AI-generated report for chest CT

  • Active comparator
    Standard Reporting

    This arm involves board-certified radiologists interpreting chest CT cases without AI assistance, following standard workflow procedures. In Phase 1 (retrospective crossover), radiologists interpret the same set of historical cases without the AI-generated draft (order randomized with a washout period). In Phase 2 (prospective real-world deployment), this arm represents routine clinical practice where no AI drafts are provided for new chest CT scans. The control condition is standard reporting without AI assistance.

    Procedure: Standard reporting procedure (no AI assistance)

Interventions

  • DeviceAI-generated report for chest CT

    A clinical decision support software generates a preliminary report draft for chest CT examinations. Board-certified radiologists then finalize the AI draft.

  • ProcedureStandard reporting procedure (no AI assistance)

    Standard chest CT reporting procedure without AI assistance. Board-certified radiologists independently interpret chest CT examinations and generate final reports following standard clinical workflow without preliminary AI-generated drafts.

06

What researchers measure

Primary outcomes

  1. Subjective report quality evaluation based on diagnostic requirements and clinical relevance

    Quality is blindly assessed by independent clinicians using pairwise comparisons among three report types: AI-generated raw reports, human-only reports, and human-AI collaborative reports. Superior reports score 1 point, ties score 0.5.

    Time frame: CT reports will be distributed for external clinician scoring once all required data are available (typically ≤ 2 weeks post Primary Completion Date); the final aggregated analysis will be completed within 4 weeks post Primary Completion Date.

  2. Significance of radiologist modifications to AI-generated reports

    Using a 5-point ordinal scale, independent external clinicians rate the clinical significance of edits made to AI reports. Level 1 denotes minimal changes; Level 5 indicates critical corrections preventing inappropriate/delayed management. Intermediate levels (2-4) represent minor adjustments, beneficial optimizations, and significant refinements impacting diagnostic clarity or treatment selection.

    Time frame: CT reports will be distributed for external clinician scoring once all required data are available (typically ≤ 2 weeks post Primary Completion Date); the final aggregated analysis will be completed within 4 weeks post Primary Completion Date.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07634861
Collaborators
Shanghai Geriatric Medical Center, Yangzhou No.1 People's Hospital, The Affiliated Hospital of Xuzhou Medical University, Affiliated Hospital of Jiangsu University, Dushu Lake Hospital Affiliated to Soochow University, China-Japan Union Hospital, Jilin University, Xiangya Hospital of Central South University, Lanzhou University Second Hospital, First Affiliated Hospital of Xinjiang Medical University, Peking University Cancer Hospital & Institute, Zhongshan Hospital (Xiamen), Fudan University, First People's Hospital of Kunming, Shanghai Minhang Central Hospital, Shanghai United Imaging Intelligence Ltd.
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Jun 20, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Jun 9, 2026

Study contacts

Xiaodan Ye, MD, PhD
Contact
yuanyxd@163.com
+86-13761459998
Weiqiu Jin, BEng, BA, MD
Contact
jinwqzsh@fudan.edu.cn
Mengsu Zeng, MD, PhD
study chair · Department of Radiology, Zhongshan Hospital, Fudan University
Dinggang Shen, PhD
study director · United Imaging Intelligence, Shanghai
Jianying Gu, MD, PhD
study director · Department of Radiology, Zhongshan Hospital, Fudan University
Dijia Wu, PhD
study director · United Imaging Intelligence, Shanghai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion